Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2012

View Archived Issues

New diacylglycerol O-acyltransferase 1 inhibitors designed

New motilin receptor agonists divulged by Daiichi Sankyo

Research at Merck & Co. yields novel candidate hepatitis C therapies

Novartis designs novel IL-12RB1-targeted antibodies

Panacea Biotec develops new neurotransmitter transporter ligands

Scientists in Japan present new agents active against drug-resistant HIV-1

First dual SPK 1/2 inhibitors discovered at Amgen

Scientists in China develop vaccine to prevent atherosclerosis in persons with diabetes

Mecasermin shows promise in Rett's syndrome

Pharmanest begins phase I trial of product for relief of pain associated with IUD insertion

Tolero and MannKind enter agreement for BTK inhibitors

Liposomal GAP-107B8 has promising pharmacokinetics in rats

FDA accepts lomitapide NDA for review

Pivotal iferanserin trial advances

Ampio completes day 84 analysis of Ampion-In-Knee study

First drug launched to reduce toxic plasma methotrexate levels

FDA approves new therapy for type 1 Gaucher's disease

Vernalis completes phase I study of adenosine A2A receptor antagonist

Study assesses Ampligen administered with FluMist

Prana Biotechnology enrolls first patient in Reach2HD study

Recruitment complete in phase IIb Synavive trial

E.U. grant issued to support development of drug for fetal growth restriction

First-in-class PI3K-delta-specific agent advances to phase III testing

AnaptysBio and Gilead Sciences sign antibody discovery partnership

ISTA reports on phase II seasonal allergic rhinitis study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...